Generate Biomedicines, Inc.
GENBNasdaq
$13.56
↓ -0.7%Jul 17 close · end-of-day
Price
1Y↑ +7.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Our principal executive offices are located in Somerville, MA.
- CEO
- Michael Nally
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 312
- Headquarters
- Massachusetts
- Website
- www.generatebiomedicines.com
Management & directors
- Nally MichaelChief Executive Officer
- Grous BethChief People Officer
- Silvers JasonPresident & CFO
Roles derived from SEC Form 4 filings.
Earnings
GENB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$7.2M↓ -18.1%
Diluted EPS-$1.07↓ -34.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | $8.8M | $7.2M |
| Gross profit | — | — |
| Operating income | -$48.2M | -$64.1M |
| Net income | -$41.7M | -$61.4M |
| Diluted EPS | -$1.62 | -$1.07 |
| Operating cash flow | -$53.2M | -$80.4M |
| Free cash flow | -$53.9M | -$84.2M |
| Gross margin | — | — |
| Operating margin | -546.1% | -887.5% |
| Net margin | -472.7% | -850.6% |
Company news
Jul 1, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-04 | Nally Michael· Chief Executive Officer | Buy | 20,000 | $12.00 | $240,000.00 | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | AFEYAN NOUBAR | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-03-02 | Mendillo Jane L | Buy | 1,500 | $16.00 | $24,000.00 | filing |
| 2026-03-02 | Silvers Jason· President & CFO | Buy | 1,000 | $16.00 | $16,000.00 | filing |
| 2026-03-02 | Silvers Jason· President & CFO | Buy | 500 | $16.00 | $8,000.00 | filing |
| 2026-03-02 | Silvers Jason· President & CFO | Buy | 500 | $16.00 | $8,000.00 | filing |
| 2026-03-02 | Grous Beth· Chief People Officer | Buy | 300 | $16.00 | $4,800.00 | filing |
| 2026-03-02 | Nally Michael· Chief Executive Officer | C | 658,327 | — | — | filing |
| 2026-03-02 | Bancel Stephane | C | 724,160 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 12,723,940 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 13,702,224 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 987,491 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 12,723,940 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 987,491 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 13,702,224 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 2,777,752 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 2,777,752 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 2,777,752 | — | — | filing |
| 2026-03-02 | AFEYAN NOUBAR | C | 2,777,752 | — | — | filing |
Latest 24 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.